June 1, 2021

Cellular and Humoral Immunogenicity of a SARS-CoV-2 MRNA Vaccine in Patients on Hemodialysis

Category: Article Summary

Topic: Vaccines and Immunity

Keywords (Tags): vaccine effectiveness

• [Pre-print, not peer-reviewed] In a cohort of patients on intermittent hemodialysis (n=81), the Pfizer-BioNTech vaccine elicited diminished anti-SARS-CoV-2 antibody responses compared to healthy controls (n=34). Plasma and saliva IgG responses and antibody binding to variants of concern were lower in dialysis patients, particularly binding against the B.1.351 variant. Consistent with humoral responses, vaccine-induced cellular immune responses assessed by T-cell mediated interferon γ release after stimulation with SARS-CoV-2 spike peptides were significantly diminished in dialysis patients.

Strengert et al. (May 29, 2021). Cellular and Humoral Immunogenicity of a SARS-CoV-2 MRNA Vaccine in Patients on Hemodialysis. Pre-print downloaded Jun 1 from https://doi.org/10.1101/2021.05.26.21257860